These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of vacuum curettage on the concentrations of plasma 6-keto-prostaglandin F1 alpha and serum thromboxane B2.
    Author: Ylikorkala O, Mäkilä UM, Viinikka L.
    Journal: Br J Obstet Gynaecol; 1983 Mar; 90(3):251-4. PubMed ID: 6338904.
    Abstract:
    Serial plasma samples collected before and after vacuum curettage followed by methylergometrine injection in 10 women were assayed for 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha). The mean 6-keto-PGF1 alpha concentration was 97.2 (SE 8.8) pg/ml before cervical dilatation. The concentration rose to 128.2 (SE 13.5) pg/ml (P less than 0.10) immediately and to 133.3 (SE 17.8) pg/ml (P less than 0.05) 1 h after curettage and returned to the initial value within 5 h. Neither methylergometrine nor anaesthesia, nor non-gynaecological surgery, caused changes in the level of plasma 6-keto-PGF1 alpha. The capacity of the platelets to produce thromboxane A2 during spontaneous clotting of blood did not change during vacuum curettage, anaesthesia and non-gynaecological surgery, nor after methylergometrine. The evidence suggests that the pregnant myometrium and/or intrauterine tissues capable of generating prostacyclin (PGI2) in vitro may release PGI2 also in vivo. Prostacyclin (PGI2) and thromboxane A2 (TXA2) are 2 new prostanoids. PGI2 is characterized by potent antiaggregatory and vasodilatory properties and TXA2 by proaggregatory and vasoconstrictor activities. Both compounds are labile and converted rapidly in aqueous buffer into their main metabolites, 6-keto-prostaglandin Flalpha (6-keto-PGFlalpha) and thromboxane B2 (TXB2). PGI2 is also produced by the pregnant cervix and several pregnancy associated intrauterine tissues "in vitro," but the contribution of these tissues to the increased circulating levels of 6-keto-PGFlalpha during pregnancy or labor is unknown. The significance of these tissues as a source of PGI2 "in vivo" was explored by studying the changes in circulating levels of 6-keto-PGFlalpha during the termination of pregnancy by vacuum curettage, when the uterus and intrauterine tissues are extensively traumatized. The effect of vacuum curettage on the production of thromboxane B2 (TXB2) by platelets was also studied. The study subjects were 16 healthy women, ranging in age from 15-26 years, who were admitted for legal abortion at between 7-12 weeks of uncomplicated pregnancy. Vacuum curettage was performed under brief anesthesia induced with 150-200 mg of methohexital sodium after an overnight fast. Blood samples were collected from the maternal antecubital vein by venepuncture. Also studied was the effect of methylergometrine only on PGI2 and TXA2 by injecting 0.2 mg of methylergometrine intravenously into 6 women on the day preceding vacuum curettage. Blood samples were collected from these women before and 10, 30, and 60 minutes after the injection. To asses the effect on anesthesia and/or nongynecological operation on PGI2 and TXA2, 6 nonpregnant women between 15-41 years operated on for nongynecological reasons were studied. The 6-keto-PGFlkalpha concentration rose immediately after curettage and remained elevated for 1 hour but returned to the initial levels 5 hours after curettage. Injection of methylergometrine and anesthesia and/or nongynecologic operation caused no changes in plasma 6-keto-PGFlalpha. Serum TXB2 concentrations did not change during vacuum curettage after the injection of methylergometrine or anesthesia and/or nongynecologic surgery.
    [Abstract] [Full Text] [Related] [New Search]